InnoCare Completes Phase II ICP-488 Psoriasis Trial Enrollment

InnoCare Pharma (HKEX: 09969; SSE: 688428), a prominent biopharmaceutical company dedicated to treating cancer and autoimmune diseases, has announced the completion of patient enrollment for its phase II clinical trial of ICP-488, a TYK2 JH2 allosteric inhibitor, aimed at treating psoriasis.

This clinical trial is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ICP-488 in Chinese adults with moderate to severe plaque psoriasis. A total of 129 patients have been enrolled and randomly assigned to one of three groups in a 1:1:1 ratio: a 6mg once-daily group, a 9mg once-daily group, and a placebo group, over a 12-week treatment period.

ICP-488 is an oral, potent, and selective TYK2 allosteric inhibitor. By binding to the JH2 domain, it blocks the signal transduction of IL-23, IL-12, type 1 interferon (IFN), and other inflammatory cytokines, thus inhibiting the pathological progression of autoimmune and inflammatory diseases. The phase I study of ICP-488 in treating psoriasis patients showed promising efficacy and safety results.

Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, stated, “Psoriasis requires long-term management, and there remains a significant unmet need for new drugs, particularly oral medications. We are very pleased to announce the completion of patient enrollment for the phase II clinical trial of ICP-488 for psoriasis treatment. Our commitment is to advance the clinical development of this promising therapy diligently, aiming to provide enhanced treatment options for psoriasis patients as soon as possible.”

Recent data reveal that approximately seven million individuals in China are living with psoriasis, and this number is increasing. Current treatment options do not fully meet the needs of those affected, highlighting a substantial gap in available therapies. There is a pronounced demand for new oral medications, as many patients with moderate-to-severe psoriasis continue to be under-treated or not treated at all.

InnoCare is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class and/or best-in-class medications for cancer and autoimmune diseases, addressing unmet medical needs in China and globally. InnoCare operates with branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!